Shaaltiel Yoseph 4
4 · Protalix BioTherapeutics, Inc. · Filed Jul 8, 2009
Insider Transaction Report
Form 4
Shaaltiel Yoseph
DirectorExecutive VP, R&D
Transactions
- Sale
Common Stock
2009-07-06$4.95/sh−20,000$99,000→ 1,363,754 total - Sale
Common Stock
2009-07-06$5.13/sh−80,000$410,400→ 1,383,754 total
Footnotes (1)
- [F1]The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.